Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma
Endoscopy International Open · 13.01.2026 · 14 (CP)
DOI: 10.1055/a-2733-1068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 13.01.2026. Verfasst von Owen McKay und 18 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Monash Health, Melbourne, Australia. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a poor prognostic malignancy. Comprehensive genomic profiling (CGP) has improved outcomes in many cancers, but widespread uptake in PDAC remains elusive. This study investigated the feasibility of using endoscopic ultrasound with fine-needle biopsy (EUS-FNB) for CGP in advanced PDAC. A multicenter prospective cohort study was conducted to assess the feasibility of using DNA and RNA extracted from fresh frozen or archival formalin-fixed paraffin-embedded (FFPE) EUS-FNB for CGP on advanced PDAC using the TSO-500 gene panel testing. Results of the CGP were reviewed at a molecular tumor board (MTB) and subsequent treatment recommendations were forwarded to the referring clinicians. CGP was successful in 129 of 143 patients (90%) enrolled between May 2020 to September 2023. Fresh frozen EUS-FNB provided suitable genetic material for CGP in 123 of 133 patients (92%). Conversely, CGP was successful on FFPE biopsy blocks from only six of 16 patients (38%). Fifty-two of 143 patients (36%) had a potentially targetable mutation detected, and eight of these patients (6%) were treated with targeted therapy based on their EUS-FNB-derived molecular profile. Patients who received personalized therapy had a significant (P < 0.0001) increase in survival versus standard or no therapy at 12 and 36 months. Median patient survival on standard therapy was 9.47 months versus > 18 months for personalized therapy. This real-world study confirms the feasibility and utility of CGP using EUS-FNB in advanced PDAC. It illustrates the importance of timely access to personalized therapy informed by CGP, which can impact the treatment pathway and improve survival outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Hepatology, Monash Health, Melbourne, Australia.
- Upper Gastrointestinal Surgery, Monash Health, Clayton, Australia.
- Medical Oncology, Peninsula Health, Frankston, Australia.
- Cancer and Immune Signalling, Hudson Institute of Medical Research, Clayton, Australia.
- Faculty of Medicine, Nursing and Health Sciences, Department of Surgery, Monash University, Melbourne, Australia.
- Gastroenterology & Hepatology, Peninsula Health, Frankston, Australia.
ORCID-Profile: Owen McKay
Zitieren
APA
McKay, O., Lundy, J., Bell, S., Ha, P., Gao, H., Jenkins, B., Bulathsinghalage, C., Swan, M., Hew, S., Lee, B., Dorwal, P., Bhutani, M. S., Rathi, V., Grimmond, S., Perry, A., Wilson, T., Strickland, A., Zalcberg, J., & Croagh, D. (2026). Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Endoscopy International Open, 14(CP). https://doi.org/10.1055/a-2733-1068
Vancouver
McKay O, Lundy J, Bell S, Ha P, Gao H, Jenkins B, et al. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Endoscopy International Open. 2026;14(CP). doi:10.1055/a-2733-1068
BibTeX
@article{McKay2026,
author = {McKay, Owen and Lundy, Joanne and Bell, Sally and Ha, Phil and Gao, Hugh and Jenkins, Brendan and Bulathsinghalage, Chamkaushalya and Swan, Michael and Hew, Simon and Lee, Belinda and Dorwal, Pranav and Bhutani, Manoop S and Rathi, Vivek and Grimmond, Sean and Perry, Andrew and Wilson, Trevor and Strickland, Andrew and Zalcberg, John and Croagh, Daniel},
title = {Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma},
journal = {Endoscopy International Open},
year = {2026},
volume = {14},
number = {CP},
doi = {10.1055/a-2733-1068}
}
EUVIMED